Lake Street Capital Initiates Coverage on LifeVantage (NASDAQ:LFVN)

Stock analysts at Lake Street Capital began coverage on shares of LifeVantage (NASDAQ:LFVN) in a report issued on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $26.00 price target on the stock. Lake Street Capital’s target price would suggest a potential upside of 49.77% from the stock’s previous close.

LifeVantage Price Performance

Shares of LFVN stock opened at $17.36 on Thursday. LifeVantage has a fifty-two week low of $5.22 and a fifty-two week high of $18.41. The stock’s 50-day moving average is $13.99 and its two-hundred day moving average is $10.31. The firm has a market cap of $217.43 million, a P/E ratio of 54.25 and a beta of 0.87.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. The firm had revenue of $47.21 million for the quarter. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%.

Institutional Trading of LifeVantage

Institutional investors and hedge funds have recently made changes to their positions in the stock. Capital Management Corp VA acquired a new position in shares of LifeVantage during the 3rd quarter valued at about $5,073,000. HighTower Advisors LLC acquired a new position in LifeVantage during the third quarter valued at approximately $638,000. Renaissance Technologies LLC raised its position in shares of LifeVantage by 2.1% in the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares during the period. Hantz Financial Services Inc. acquired a new stake in shares of LifeVantage in the second quarter worth $91,000. Finally, Barclays PLC boosted its holdings in shares of LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after buying an additional 11,608 shares during the period. Institutional investors and hedge funds own 35.32% of the company’s stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.